ModifiedHealth NetPolicy CP PHAR.334

Ribociclib (Kisqali) and Ribociclib/Letrozole (Kisqali Femara) coverage

Defines medical necessity criteria, authorization requirements, and approval durations for ribociclib (Kisqali) and the ribociclib/letrozole combination (Kisqali Femara) for Health Net lines of business including Commercial, HIM, and Medicaid.

Policy Summary

PayerHealth Net

PolicyRibociclib (Kisqali) and Ribociclib/Letrozole (Kisqali Femara) coverage

Policy CodePolicy CP PHAR.334

Change TypeMaterial clinical updates and indication expansion

Effective Date05.01.17

Next Review Date

Key ActionSubmit prior authorization with documentation of diagnosis, prescriber specialty, age, receptor/HER2 status, dosing regimen, and ovarian ablation/suppression when applicable.

SourceLink

POLICY UPDATE CHANGES

Added criteria for newly approved indication for adjuvant treatment of adults with HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence.

Updated FDA approved indication for use in combination with fulvestrant to include perimenopausal females and added requirement for ovarian ablation/suppression.

Clarified maximum dosing for Kisqali and Kisqali Femara by separating dosing into two criteria for initial approval and continued therapy sections.

>=18Minimum age requirement

3 yrsEarly breast cancer duration

600 mgMax dose (advanced)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Ribociclib (Kisqali) and Kisqali Femara

Initial Approval Criteria

Covered when ALL of the following are met for initial therapy (breast cancer):

Diagnosis of breast cancer.

Prescriber: Prescribed by or in consultation with an oncologist.

Age: Patient is >= 18 years of age.>= 18 years

Hormone receptor and HER2 status: Disease is HR-positive (ER and/or PR positive) and HER2-negative.

Stage/setting: Either advanced/recurrent/metastatic disease OR stage II/III early breast cancer at high risk of recurrence.

Combination therapy: If request is for Kisqali, therapy must be in combination with an aromatase inhibitor or fulvestrant; if Kisqali Femara, prescribed as initial endocrine-based therapy or adjuvant therapy with letrozole.

Premenopausal females: If premenopausal or perimenopausal, member must have ovarian ablation or be receiving ovarian suppression.

See Appendix D for details on ovarian ablation/suppression.

Males on aromatase inhibitor: If male and receiving an aromatase inhibitor, therapy must be combined with an agent that suppresses testicular steroidogenesis (e.g., GnRH agonist).

No prior CDK4/6 progression: Member must not have previously experienced disease progression on a CDK4/6 inhibitor therapy.

Not concurrent CDK4/6: Requested agent is not prescribed concurrently with another CDK4/6 inhibitor.

Dose limits by indication: Dose must not exceed specified limits by indication (examples: Kisqali up to 600 mg/day for advanced/metastatic; Kisqali 400 mg/day for early breast cancer when indicated) or be supported by guidelines/literature for off-label use.Kisqali 400 mg–600 mg per day for 21 of 28 days depending on scenario

Prescribed regimen must be FDA-approved or recommended by NCCN.

Generic use: For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced.

Continuation Therapy Criteria

Covered when ALL of the following are met for continued therapy:

Current therapy: Member is currently receiving the medication via the benefit or documentation supports that the member has been receiving Kisqali or Kisqali Femara for at least 21 days.>= 21 days

Clinical response: Member is responding positively to therapy.

No concurrent CDK4/6: Requested agent is not prescribed concurrently with another CDK4/6 inhibitor.

Dose changes and limits: If request is for a dose increase, the new dose must not exceed defined maximums (e.g., Kisqali up to 600 mg/day for advanced; Kisqali up to 400 mg/day for early breast cancer when applicable) or must be supported by practice guidelines or peer-reviewed literature for off-label uses.

Endometrial Carcinoma (off-label) Criteria

Off-label indication: Endometrial carcinoma (coverage considered when ALL of the following are met):

Diagnosis of endometrial carcinoma.

Prescriber: Prescribed by or in consultation with an oncologist.

Age: Patient is >= 18 years of age.>= 18 years

Combination: If request is for Kisqali, it must be prescribed in combination with letrozole.

Tumor ER status:

Indication-aligned dosing and duration

Coverage aligned to indication and dosing:

Advanced or metastatic breast cancer dosing: For advanced or metastatic breast cancer: ribociclib (Kisqali) 600 mg PO once daily for 21 consecutive days followed by 7 days off; when combined with letrozole, add letrozole 2.5 mg PO once daily on a 28-day cycle.maximum 600 mg/day

Early breast cancer dosing and duration: For early breast cancer: ribociclib 400 mg PO once daily for 21 consecutive days followed by 7 days off; when combined with letrozole, letrozole 2.5 mg PO once daily; treatment should continue for 3 years or until disease recurrence or unacceptable toxicity.maximum 400 mg/day; duration: 3 years

Dose reduction rule: If a dose reduction to 200 mg/day is required, therapy should be discontinued.200 mg/day

Requests for indications that are not FDA‑approved and are not explicitly addressed in this policy are excluded unless the provider supplies sufficient supporting documentation demonstrating efficacy and safety per applicable off‑label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for marketplace, or CP PMN.53 for Medicaid).

Concurrent administration of ribociclib (Kisqali) with tamoxifen is discouraged and considered contraindicated due to increased risk of QT prolongation; this combination has been removed from NCCN support and is noted in the product safety information.

Use of ribociclib for non‑FDA approved indications without submission of sufficient off‑label documentation as required by the referenced off‑label policies is not authorized; providers must supply evidence of efficacy and safety consistent with the applicable off‑label coverage rules for the request to be considered.

Retreatment by starting a different CDK4/6 inhibitor after disease progression on a prior CDK4/6 inhibitor is not supported by available data and therefore is considered not medically necessary.

Initial Therapy Criteria and Dosing

Initial Therapy

Initial therapy coverage requires meeting clinical and regimen-specific criteria:

Diagnosis and receptor testing: Diagnosis of appropriately receptor-defined breast cancer (HR-positive, HER2-negative) or other approved/off-label indications as specified.

Prescriber: Prescribed by or in consultation with an oncologist.

Combination regimens: Kisqali must be combined with an aromatase inhibitor or fulvestrant as indicated; Kisqali Femara must be prescribed with letrozole for its labeled uses.

No prior CDK4/6 progression: No prior disease progression on a CDK4/6 inhibitor.

Continuation Therapy and Maintenance

Continuation

Continued therapy is approved when the member is benefiting and criteria are met:

Duration on therapy: Member has received medication for at least 21 days or is currently receiving via the benefit.>= 21 days

Clinical benefit: Member is responding positively to therapy.

Continuation therapy

Continuation criteria reflect maintenance of dosing/duration and maximum dose limits.

Continued therapy after initial approval: Continued therapy should maintain dosing within maximums (600 mg/day for advanced; 400 mg/day for early) and be discontinued if dose reduction to 200 mg/day is required or if unacceptable toxicity or disease recurrence occurs.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must submit documentation (e.g., office chart notes, laboratory results, imaging, pathology, treatment history) demonstrating that the member meets all applicable approval criteria, including diagnosis, prescriber specialty, age, receptor status, planned regimen and duration.

Include chart notes showing diagnosis and staging
Provide documentation of biomarker status (HR-positive, HER2-negative as applicable)
If premenopausal/perimenopausal, document ovarian ablation or suppression when an aromatase inhibitor is used
If male receiving an aromatase inhibitor, document concurrent testicular suppression agent

Documentation Required

Non‑FDA Approved Indications

Requests for indications that are not FDA‑approved and not explicitly addressed in this policy will not be authorized unless the provider supplies sufficient supporting evidence of efficacy and safety in accordance with the applicable off‑label use policy for the member's line of business.

Product Coding and Key Values

Product availabilitymixed

Tablet: 200 mg

Ribociclib tablet strength availability

Early breast cancer treatment duration

Early breast cancer treatment duration3 years (continue treatment for 3 years or until disease recurrence or unacceptable toxicity)

Applicable dosing scheduleKisqali 400 mg PO once daily for 21 days followed by 7 days off when used for early breast cancer

Letrozole (Femara) dosing when combinedLetrozole 2.5 mg PO once daily in a 28-day cycle

Required clinical documentation — dosing & duration

Required documentation elementsDocument indication (early vs advanced/metastatic), selected dosing regimen, and planned duration (e.g., 3 years for early breast cancer)

Kisqali dosing to documentFor early breast cancer: 400 mg PO QD for 21 days followed by 7 days off; for advanced/metastatic: 600 mg PO QD for 21 days followed by 7 days off

Step Therapy and Prior Exposure Requirements

Requirement	Details
Generic-first requirement
For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced.

Requirement	Details
Prior CDK4/6 exposure documentation
Prior history of CDK4/6 inhibitor exposure must be documented; policy notes that member must not have previously experienced disease progression on a CDK4/6 inhibitor and earlier edits added that member has not previously failed another CDK4/6 inhibitor therapy, with line-of-business edits potentially requiring lack of prior failure.

Quantity Limits and Formulations

Ribociclib product availability

Tablet strength availableRibociclib (Kisqali): Tablet — 200 mg

Product formOral tablet formulation

Combination product listingRibociclib/letrozole (Kisqali Femara) availability noted in product availability section

Site of Care

Note

Site‑of‑care: infusion center

No site‑of‑care restriction is specified in this portion of the document.

Infusion center or other site‑of‑care limitations are not imposed in this excerpt

Background

Ribociclib is a CDK4/6 inhibitor used in combination with endocrine therapy for hormone receptor–positive, HER2‑negative breast cancer. Typical dosing for advanced/metastatic disease is 600 mg PO once daily for 21 days followed by 7 days off; for early high‑risk adjuvant use the dose is 400 mg PO once daily for 21 days followed by 7 days off, with treatment in the early breast cancer setting continued for 3 years or until recurrence or unacceptable toxicity. When combined with letrozole (an aromatase inhibitor), letrozole is given at 2.5 mg PO once daily. The NCCN and product information also note cardiac monitoring considerations, including QT risks with certain combinations.

Definitions and Abbreviations

Abbreviations

CDKCyclin-dependent kinase

HRHormone receptor

EREstrogen receptor

HER2Human epidermal growth factor receptor 2

PRProgesterone receptor

Ovarian ablation — definition

Definition of ovarian ablationSurgical oophorectomy or ovarian irradiation to stop ovarian estrogen production